source
- FDA Approves Adjuvant Atezolizumab for MRD+ Muscle-Invasive Bladder CancerThe FDA approved adjuvant atezolizumab for muscle-invasive bladder cancer with circulating tumor DNA molecular residual disease.onclive · 2mo ago↗ source
- Detalimogene Voraplasmid Yields 54% CR Rate in Heavily Pretreated BCG-Unresponsive NMIBC With CISTRAEs were generally reversible and low grade, and 96.8% of patients remained free from progression to T2 or greater disease at the data cutoff.onclive · 2mo ago↗ source
- Roswell Park Team Members Take Part in Global Conference Dedicated to Indigenous Peoples and CancerMembers of Roswell Park Comprehensive Cancer Center participated in the 2026 World Indigenous Cancer Conference.onclive